Etentamig (ABBV-383) clinical trials

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

This study looks at a new medicine called etentamig (ABBV-383) for multiple myeloma that has come back or isn't responding to other treatments. It aims to find out about any side effects and how it affects the disease in adults.